Valacyclovir Hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318966

CAS#: 124832-27-5

Description: Valacyclovir is a nucleoside analogue DNA polymerase inhibitor. Valacyclovir hydrochloride is rapidly converted to acyclovir which has demonstrated antiviral activity against HSV types 1 (HSV-1) and 2 (HSV-2) and VZV both in cell culture and in vivo. The EC50 values against herpes simplex virus isolates range from 0.09 to 60 μM (0.02 to 13.5 mcg/mL) for HSV-1 and from 0.04 to 44 μM (0.01 to 9.9 mcg/mL) for HSV-2. The EC50 values for acyclovir against most laboratory strains and clinical isolates of VZV range from 0.53 to 48 μM (0.12 to 10.8 mcg/mL). Acyclovir also demonstrates activity against the Oka vaccine strain of VZV with a mean EC50 of 6 μM (1.35 mcg/mL).


Price and Availability

Size
Price

50mg
USD 250
500mg
USD 950
Size
Price

100mg
USD 450
1g
USD 1650
Size
Price

200mg
USD 650
2g
USD 2450

Valacyclovir Hydrochloride, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318966
Name: Valacyclovir Hydrochloride
CAS#: 124832-27-5
Chemical Formula: C13H21ClN6O4
Exact Mass:
Molecular Weight: 360.799
Elemental Analysis: C, 43.28; H, 5.87; Cl, 9.83; N, 23.29; O, 17.74


Related CAS #: 124832-27-5 (HCl)   124832-26-4 (free base)  

Synonym: 256U; 256U87; Vacyclovir, L-valyl ester; BW256U87; L-valylacyclovir; Valacyclovir Hydrochloride; Valtrex; Zelitrex.

IUPAC/Chemical Name: 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate hydrochloride

InChi Key: ZCDDBUOENGJMLV-QRPNPIFTSA-N

InChi Code: InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1

SMILES Code: CC(C)[C@H](N)C(OCCOCN1C=NC2=C1NC(N)=NC2=O)=O.[H]Cl


Technical Data

Appearance:
White solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Acyclovir versus Valacyclovir for Herpes Virus in Children and Pregnant Women: A Review of the Clinical Evidence and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Sep 05. Available from http://www.ncbi.nlm.nih.gov/books/NBK253720/ PubMed PMID: 25411683.

2: Reischig T, Kacer M. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):771-9. doi: 10.1586/14737167.2014.965157. Epub 2014 Sep 25. Review. PubMed PMID: 25252996.

3: Rajalakshmi R, Kumari R, Thappa DM. Acyclovir versus valacyclovir. Indian J Dermatol Venereol Leprol. 2010 Jul-Aug;76(4):439-44. doi: 10.4103/0378-6323.66577. Review. PubMed PMID: 20657140.

4: Vigil KJ, Chemaly RF. Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults. Expert Opin Pharmacother. 2010 Aug;11(11):1901-13. doi: 10.1517/14656566.2010.494179. Review. PubMed PMID: 20536295.

5: Asahi T, Tsutsui M, Wakasugi M, Tange D, Takahashi C, Tokui K, Okazawa S, Okudera H. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol. 2009 Apr;16(4):457-60. doi: 10.1111/j.1468-1331.2008.02527.x. Review. PubMed PMID: 19187258.

6: Brantley JS, Hicks L, Sra K, Tyring SK. Valacyclovir for the treatment of genital herpes. Expert Rev Anti Infect Ther. 2006 Jun;4(3):367-76. Review. PubMed PMID: 16771614.

7: Chakrabarty A, Anderson NJ, Beutner R, Tyring SK. Valacyclovir for the management of herpes viral infections. Skin Therapy Lett. 2005 Feb;10(1):1-4. Review. PubMed PMID: 15776202.

8: Wu JJ, Brentjens MH, Torres G, Yeung-Yue K, Lee P, Tyring SK. Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections. J Cutan Med Surg. 2003 Sep-Oct;7(5):372-81. Epub 2003 Sep 24. Review. PubMed PMID: 14505192.

9: Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O'Neill W. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs Today (Barc). 2002 Aug;38(8):549-61. Review. PubMed PMID: 12582420.

10: Griffiths PD. Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir. J Infect Dis. 2002 Oct 15;186 Suppl 1:S131-7. Review. PubMed PMID: 12353198.

11: Squifflet JP, Legendre C. The economic value of valacyclovir prophylaxis in transplantation. J Infect Dis. 2002 Oct 15;186 Suppl 1:S116-22. Review. PubMed PMID: 12353196.

12: Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis. 2002 Oct 15;186 Suppl 1:S40-6. Review. PubMed PMID: 12353186.

13: Baker DA. Valacyclovir in the treatment of genital herpes and herpes zoster. Expert Opin Pharmacother. 2002 Jan;3(1):51-8. Review. PubMed PMID: 11772333.

14: Dekker CL, Prober CG. Pediatric uses of valacyclovir, penciclovir and famciclovir. Pediatr Infect Dis J. 2001 Nov;20(11):1079-81. Review. PubMed PMID: 11734715.

15: Biernat-Sudolska M. [Valacyclovir]. Przegl Lek. 1998;55(11):596-8. Review. Polish. PubMed PMID: 10216374.

16: Grose C, Wiedeman J. Generic acyclovir vs. famciclovir and valacyclovir. Pediatr Infect Dis J. 1997 Sep;16(9):838-41. Review. PubMed PMID: 9306476.

17: Stein GE. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J Am Pharm Assoc (Wash). 1997 Mar-Apr;NS37(2):157-63. Review. PubMed PMID: 9069689.

18: Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother. 1997 Feb;31(2):185-91. Review. PubMed PMID: 9034421.

19: Raffi F. [Future prospects of valacyclovir in treating and preventing herpesviridae infections in immunosuppressed patients]. Presse Med. 1997 Jan;26 Suppl 1:19-21. Review. French. PubMed PMID: 9082437.

20: Smiley ML, Murray A, de Miranda P. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Adv Exp Med Biol. 1996;394:33-9. Review. PubMed PMID: 8815698.